Arcturus Therapeutics Appoints Dennis Mulroy as New Chief Financial Officer

summarizeSummary

Arcturus Therapeutics has appointed Dennis Mulroy, a seasoned financial executive, as its new Chief Financial Officer, signaling a move to bolster financial leadership amidst recent operational challenges.

check_boxKey Events

• New Chief Financial Officer Appointed

  Dennis Mulroy, 71, has been appointed as the Chief Financial Officer, effective May 1, 2026. He will become the principal financial officer after the Q1 2026 10-Q filing.

• Experienced Financial Leader Joins

  Mr. Mulroy brings over 40 years of financial and operational leadership, having previously served as CFO for AnaptysBio, Inc. from July 2020 to April 2026 and La Jolla Pharmaceutical Company from April 2015 to May 2020.

• Compensation Package Detailed

  Mulroy's compensation includes an annual base salary of $520,000, eligibility for a 40% annual bonus, and options to acquire 100,000 shares of common stock vesting over four years.

• Interim Officer Continues in Accounting Role

  Joe Roberts, who served as interim principal financial officer, will continue as interim principal accounting officer and Controller.

auto_awesomeAnalysis

This 8-K announces the appointment of an experienced Chief Financial Officer, Dennis Mulroy, which is a significant move for Arcturus Therapeutics, especially following the recent disclosure of a substantial decline in Q1 2026 revenue and increased net loss. Mulroy's extensive background in financial and operational leadership, including previous CFO roles at AnaptysBio and La Jolla Pharmaceutical Company, suggests a strategic effort to strengthen the company's financial management and stability. His appointment could help restore investor confidence and guide the company through its current financial challenges and pipeline advancements.